Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences (FBRX) Common Equity (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Common Equity for 5 consecutive years, with $20.3 million as the latest value for Q3 2020.

  • Quarterly Common Equity rose 727.9% to $20.3 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $20.3 million through Sep 2020, up 727.9% year-over-year, with the annual reading at -$4.8 million for FY2019, 547.96% down from the prior year.
  • Common Equity for Q3 2020 was $20.3 million at Forte Biosciences, down from $24.9 million in the prior quarter.
  • The five-year high for Common Equity was $88.6 million in Q2 2017, with the low at -$132.9 million in Q1 2017.
  • Average Common Equity over 5 years is $10.1 million, with a median of $9.8 million recorded in 2018.
  • The sharpest move saw Common Equity tumbled 547.96% in 2019, then surged 1076.37% in 2020.
  • Over 5 years, Common Equity stood at -$124.4 million in 2016, then soared by 157.13% to $71.1 million in 2017, then crashed by 101.04% to -$736000.0 in 2018, then crashed by 547.96% to -$4.8 million in 2019, then skyrocketed by 526.06% to $20.3 million in 2020.
  • According to Business Quant data, Common Equity over the past three periods came in at $20.3 million, $24.9 million, and -$6.8 million for Q3 2020, Q2 2020, and Q1 2020 respectively.